---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-115766"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T08:41:14.479520+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cryoport Q3 revenue down 7% YoY, net loss widens to $0.31/share; affirms FY guidance

## Summary
- Q3 revenue $56.2M (-7% YoY); net loss $15.3M ($0.31 loss per share) vs $7.3M ($0.15 loss) in Q3 2022.
- Adjusted EBITDA negative $3.1M (vs positive $4.7M a year ago); operating costs rose to $41.2M.
- Commercial cell/gene therapy revenue up 54% to $6.6M; supports record 670 clinical trials (81 Phase 3).
- Affirms FY2023 revenue guidance $233-243M; cash & investments $465.9M at quarter end.
- Repurchased $31.3M of convertible notes for $25.1M, recording $5.7M gain on debt extinguishment.

## SEC filing metadata
- accession: 0001104659-23-115766
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465923115766/0001104659-23-115766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465923115766/tm2330255d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-115766
- JSON: https://secwatch.observer/filing/0001104659-23-115766.json
- Plain text: https://secwatch.observer/filing/0001104659-23-115766.txt

## Key facts
- Earnings Releases
  Cryoport, Inc. reported the third quarter ended September 30, 2023 results: revenue $56.2 million. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $56.2 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: new therapy approvals and an additional seven label/ geographic expansions or moves to earlier lines of treatment approved. Financial Highlights Total revenue for Q3 2023 was $56.2 million compared to $60.5 million for Q3 2022, a year-over-year decrease of 7% or $4.3 million. • Biopharma/Pharma revenue was $47.0 million, down 3% or $1.6 million for Q3 2023 compared
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124524/000110465923115766/0001104659-23-115766-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.